Allurion 可吞咽胃内球囊短期减肥的有效性和安全性：系统评价和荟萃分析。
Effectiveness and Safety of the Allurion Swallowable Intragastric Balloon for Short-term Weight Loss: A Systematic Review and Meta-analysis.
机构信息
Gastrointestinal Endoscopy Service, Hospital das Clínicas HCFMUSP, Department of Gastroenterology, Faculty of Medicine, University of São Paulo, São Paulo, SP, Brazil.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Department of Gastroenterology,, Gastrointestinal Endoscopy Unit, Av. Dr. Enéas de Carvalho Aguiar, 255 Central Institute - Outpatient Building, Cerqueira César, São Paulo, SP, CEP: 05403-000, Brazil.
出版信息
Obes Surg. 2024 Oct;34(10):3735-3747. doi: 10.1007/s11695-024-07453-5. Epub 2024 Aug 23.
BACKGROUND
Obesity poses a severe health problem worldwide, with an estimated impact on 17.5% of the adult population by 2035. Among the endoscopic applications for treating this comorbidity, intragastric balloons are the most widely used. The new liquid-filled swallowable balloon meets the requirements of major guidelines and allows significant weight loss with few adverse events. This systematic review and meta-analysis aims to demonstrate the efficacy and safety profile of this new device for weight loss.
METHODS
We conducted a search from 2016 to 2024 to assess the efficacy of the swallowable intragastric balloon for weight loss, including improvements in metabolic profiles and anthropometric measurements. Additionally, we evaluated potential adverse events related to the device to demonstrate its safety.
RESULTS
Eleven observational studies totalling 2107 patients were included, showing a reduction of 4.75 in BMI (95% CI: -5.02; -4.47), a mean total weight loss of 12.47% (95% CI: -13.77; -11.17), a mean excess weight loss of 48.04% (95% CI: -50.61; -45.48), and a rate of serious adverse events of 0.90%. An improvement in the metabolic profile was observed for three parameters: HDL, triglycerides, and glycaemia.
CONCLUSION
The swallowable liquid-filled intragastric balloon is safe and effective for managing weight loss within a four-month follow-up period.
背景
肥胖是一个全球性的严重健康问题，预计到 2035 年，全球将有 17.5%的成年人受到影响。在治疗这种合并症的内镜应用中，胃内球囊是最广泛使用的。新型可吞咽的充液球囊符合主要指南的要求，可以显著减轻体重，且不良事件较少。本系统评价和荟萃分析旨在展示这种新型减肥装置的疗效和安全性。
方法
我们从 2016 年到 2024 年进行了检索，以评估可吞咽的胃内球囊在减肥方面的疗效，包括改善代谢谱和人体测量学指标。此外，我们还评估了与该装置相关的潜在不良事件，以证明其安全性。
结果
共纳入 11 项观察性研究，总计 2107 例患者，结果显示 BMI 降低了 4.75（95%CI：-5.02；-4.47），平均总减重 12.47%（95%CI：-13.77；-11.17），平均多余体重减轻 48.04%（95%CI：-50.61；-45.48），严重不良事件发生率为 0.90%。三个参数的代谢谱得到改善：高密度脂蛋白、甘油三酯和血糖。
结论
在四个月的随访期间，可吞咽的充液胃内球囊是安全有效的，可用于管理体重减轻。
Zotero 插件